Insider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Sells 1,277 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) Director Gerard Ber sold 1,277 shares of the business’s stock in a transaction dated Tuesday, May 10th. The stock was sold at an average price of $58.19, for a total transaction of $74,308.63. Following the transaction, the director now owns 32,703 shares in the company, valued at $1,902,987.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Lantheus stock opened at $59.60 on Friday. The firm has a fifty day moving average of $57.43 and a two-hundred day moving average of $38.66. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.64 and a current ratio of 1.83. The company has a market cap of $4.09 billion, a P/E ratio of -104.56, a PEG ratio of 0.62 and a beta of 0.76. Lantheus Holdings, Inc. has a one year low of $19.30 and a one year high of $69.74.

Lantheus (NASDAQ:LNTHGet Rating) last posted its earnings results on Friday, April 29th. The medical equipment provider reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.51. Lantheus had a negative net margin of 6.89% and a positive return on equity of 19.83%. The firm had revenue of $208.90 million during the quarter, compared to the consensus estimate of $165.30 million. During the same period last year, the firm posted $0.05 EPS. The firm’s revenue for the quarter was up 125.8% on a year-over-year basis. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 2.78 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd acquired a new stake in shares of Lantheus in the third quarter worth approximately $43,000. City State Bank bought a new stake in shares of Lantheus in the fourth quarter worth $60,000. Macquarie Group Ltd. increased its stake in shares of Lantheus by 218.5% in the third quarter. Macquarie Group Ltd. now owns 2,838 shares of the medical equipment provider’s stock worth $73,000 after buying an additional 1,947 shares during the last quarter. First Manhattan Co. boosted its holdings in Lantheus by 39.5% in the third quarter. First Manhattan Co. now owns 4,324 shares of the medical equipment provider’s stock worth $111,000 after purchasing an additional 1,224 shares during the period. Finally, O Shaughnessy Asset Management LLC boosted its holdings in shares of Lantheus by 20.7% during the third quarter. O Shaughnessy Asset Management LLC now owns 5,056 shares of the medical equipment provider’s stock valued at $130,000 after acquiring an additional 866 shares during the period. 97.14% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on LNTH shares. Truist Financial boosted their price target on shares of Lantheus from $77.00 to $94.00 in a research note on Monday, May 2nd. Zacks Investment Research upgraded shares of Lantheus from a “sell” rating to a “hold” rating and set a $74.00 price target for the company in a report on Tuesday, May 3rd. B. Riley assumed coverage on shares of Lantheus in a report on Monday. They issued a “buy” rating and a $91.00 target price for the company. assumed coverage on shares of Lantheus in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, SVB Leerink increased their price target on shares of Lantheus from $34.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, February 24th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Lantheus presently has an average rating of “Buy” and a consensus target price of $83.50.

Lantheus Company Profile (Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Featured Stories

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.